{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:06:15Z","timestamp":1782781575755,"version":"3.54.5"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5,11]]},"DOI":"10.1097\/qad.0b013e3282ff6275","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T11:29:25Z","timestamp":1209900565000},"page":"937-945","source":"Crossref","is-referenced-by-count":103,"title":["Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response"],"prefix":"10.1097","volume":"22","author":[{"given":"Huong Q","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia S","family":"Magaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari M","family":"Kitahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E","family":"Van Rompaey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Casper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210130","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/94.16.1204","article-title":"Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998","volume":"94","author":"Eltom","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R2-4-20210130","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ctrv.2006.06.001","article-title":"Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives","volume":"32","author":"Vanni","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"R3-4-20210130","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1097\/00002030-199910220-00014","article-title":"Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma","volume":"13","author":"Bower","year":"1999","journal-title":"AIDS"},{"key":"R4-4-20210130","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ijc.10274","article-title":"Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma","volume":"98","author":"Tam","year":"2002","journal-title":"Int J Cancer"},{"key":"R5-4-20210130","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2001.19.18.3848","article-title":"Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy","volume":"19","author":"Holkova","year":"2001","journal-title":"J Clin Oncol"},{"key":"R6-4-20210130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00042560-200206010-00015","article-title":"Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone","volume":"30","author":"Paparizos","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-4-20210130","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00126334-200212010-00003","article-title":"Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma\u2013associated herpesvirus infection in patients with and without Kaposi sarcoma","volume":"31","author":"Gill","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-4-20210130","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/01.aids.0000131385.60974.b9","article-title":"Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma","volume":"18","author":"Martin-Carbonero","year":"2004","journal-title":"AIDS"},{"key":"R9-4-20210130","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0959-8049(99)00161-6","article-title":"Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome","volume":"35","author":"Cattelan","year":"1999","journal-title":"Eur J Cancer"},{"key":"R10-4-20210130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/oxfordjournals.jncimonographs.a024256","article-title":"Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome","volume":"28","author":"Cattelan","year":"2000","journal-title":"J Natl Cancer Inst Monogr"},{"key":"R11-4-20210130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s15010-005-4099-z","article-title":"Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery","volume":"33","author":"Lichterfeld","year":"2005","journal-title":"Infection"},{"key":"R12-4-20210130","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1097\/00002030-200211220-00019","article-title":"The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma","volume":"16","author":"Esdaile","year":"2002","journal-title":"AIDS"},{"key":"R13-4-20210130","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1093\/annonc\/mdg461","article-title":"Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations","volume":"14","author":"Stebbing","year":"2003","journal-title":"Ann Oncol"},{"key":"R14-4-20210130","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1310\/700B-9QT3-HGN9-Q3FQ","article-title":"Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy","volume":"2","author":"Nunez","year":"2001","journal-title":"HIV Clin Trials"},{"key":"R15-4-20210130","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/01.aids.0000222074.45372.00","article-title":"Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy","volume":"20","author":"Crane","year":"2006","journal-title":"AIDS"},{"key":"R16-4-20210130","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/368085","article-title":"Electronic human immunodeficiency virus (HIV) clinical reminder system improves adherence to practice guidelines among the University of Washington HIV Study Cohort","volume":"36","author":"Kitahata","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R17-4-20210130","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.1997.15.9.3085","article-title":"AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee","volume":"15","author":"Krown","year":"1997","journal-title":"J Clin Oncol"},{"key":"R18-4-20210130","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1258\/0956462042563666","article-title":"Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death","volume":"15","author":"Kitahata","year":"2004","journal-title":"Int J STD AIDS"},{"key":"R19-4-20210130","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1182\/blood.V99.10.3771","article-title":"Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma","volume":"99","author":"Pati","year":"2002","journal-title":"Blood"},{"key":"R20-4-20210130","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hernan","year":"2000","journal-title":"Epidemiology"},{"key":"R21-4-20210130","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/00002030-200005260-00010","article-title":"Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine","volume":"14","author":"Dupont","year":"2000","journal-title":"AIDS"},{"key":"R22-4-20210130","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2133.1999.02818.x","article-title":"The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma","volume":"140","author":"Dupin","year":"1999","journal-title":"Br J Dermatol"},{"key":"R23-4-20210130","doi-asserted-by":"crossref","first-page":"F45","DOI":"10.1097\/00002030-199807000-00002","article-title":"Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma","volume":"12","author":"Lebbe","year":"1998","journal-title":"AIDS"},{"key":"R24-4-20210130","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/QAD.0b013e328182df03","article-title":"Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART\/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma","volume":"21","author":"Bihl","year":"2007","journal-title":"AIDS"},{"key":"R25-4-20210130","first-page":"779","article-title":"Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy","volume":"27","author":"Cattelan","year":"2005","journal-title":"Int J Oncol"},{"key":"R26-4-20210130","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1046\/j.0022-202x.2001.01465.x","article-title":"Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy","volume":"117","author":"Pellet","year":"2001","journal-title":"J Invest Dermatol"},{"key":"R27-4-20210130","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/sj.bjc.6603056","article-title":"Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy","volume":"94","author":"Martinez","year":"2006","journal-title":"Br J Cancer"},{"key":"R28-4-20210130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cncr.10634","article-title":"Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma","volume":"95","author":"Tulpule","year":"2002","journal-title":"Cancer"},{"key":"R29-4-20210130","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2003.10.162","article-title":"AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era: the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals","volume":"21","author":"Nasti","year":"2003","journal-title":"J Clin Oncol"},{"key":"R30-4-20210130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ijc.2910360109","article-title":"Endemic African Kaposi's sarcoma is not associated with immunodeficiency","volume":"36","author":"Kestens","year":"1985","journal-title":"Int J Cancer"},{"key":"R31-4-20210130","first-page":"309","article-title":"Interactions between HIV-1 Tat and KSHV","volume":"312","author":"Aoki","year":"2007","journal-title":"Curr Top Microbiol Immunol"},{"key":"R32-4-20210130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/ijc.11648","article-title":"The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma","volume":"108","author":"Stebbing","year":"2004","journal-title":"Int J Cancer"},{"key":"R33-4-20210130","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/00002030-200307250-00001","article-title":"A comparison of regimens based on nonnucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma","volume":"17","author":"Portsmouth","year":"2003","journal-title":"AIDS"},{"key":"R34-4-20210130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1172\/JCI200417803","article-title":"Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis","volume":"113","author":"Grundhoff","year":"2004","journal-title":"J Clin Invest"},{"key":"R35-4-20210130","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1128\/JVI.74.2.684-692.2000","article-title":"Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir","volume":"74","author":"Gustafson","year":"2000","journal-title":"J Virol"},{"key":"R36-4-20210130","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jac\/49.2.359","article-title":"Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase","volume":"49","author":"Lock","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R37-4-20210130","doi-asserted-by":"crossref","first-page":"13427","DOI":"10.1074\/jbc.M011314200","article-title":"Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1","volume":"276","author":"Huang","year":"2001","journal-title":"J Biol Chem"},{"key":"R38-4-20210130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nm0302-225","article-title":"HIV protease inhibitors are potent antiangiogenic molecules and promote regression of Kaposi sarcoma","volume":"8","author":"Sgadari","year":"2002","journal-title":"Nat Med"},{"key":"R39-4-20210130","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J Clin Oncol"},{"key":"R40-4-20210130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0140-6736(95)92654-2","article-title":"Treatment of HIV-associated Kaposi's sarcoma with paclitaxel","volume":"346","author":"Saville","year":"1995","journal-title":"Lancet"},{"key":"R41-4-20210130","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/0140-6736(93)91147-E","article-title":"Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma","volume":"341","author":"Presant","year":"1993","journal-title":"Lancet"},{"key":"R42-4-20210130","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1200\/JCO.1984.2.10.1115","article-title":"Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine","volume":"2","author":"Laubenstein","year":"1984","journal-title":"J Clin Oncol"},{"key":"R43-4-20210130","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1200\/JCO.1995.13.4.914","article-title":"Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma","volume":"13","author":"Harrison","year":"1995","journal-title":"J Clin Oncol"},{"key":"R44-4-20210130","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1097\/00002030-199212000-00010","article-title":"AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin","volume":"6","author":"Caumes","year":"1992","journal-title":"AIDS"},{"key":"R45-4-20210130","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1634\/theoncologist.12-1-114","article-title":"A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma","volume":"12","author":"Cooley","year":"2007","journal-title":"Oncologist"},{"key":"R46-4-20210130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.1998.16.2.683","article-title":"Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Grokkup","volume":"16","author":"Stewart","year":"1998","journal-title":"J Clin Oncol"},{"key":"R47-4-20210130","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2354.2005.00567.x","article-title":"Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions","volume":"14","author":"Hernandez-Morales","year":"2005","journal-title":"Eur J Cancer Care (Engl)"},{"key":"R48-4-20210130","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","article-title":"Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma","volume":"14","author":"Gill","year":"1996","journal-title":"J Clin Oncol"},{"key":"R49-4-20210130","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-102-2-200","article-title":"Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome","volume":"102","author":"Mintzer","year":"1985","journal-title":"Ann Intern Med"},{"key":"R50-4-20210130","first-page":"259","article-title":"Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group","volume":"6","author":"Fischl","year":"1993","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R51-4-20210130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00000421-199008000-00010","article-title":"Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine","volume":"13","author":"Gill","year":"1990","journal-title":"Am J Clin Oncol"},{"key":"R52-4-20210130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"R53-4-20210130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/(SICI)1097-0215(20000101)85:1<54::AID-IJC10>3.0.CO;2-D","article-title":"Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry","volume":"85","author":"Chokunonga","year":"2000","journal-title":"Int J Cancer"},{"key":"R54-4-20210130","first-page":"1585","article-title":"Trends in cancer incidence in Kyadondo County, Uganda, 1960\u20131997","volume":"82","author":"Wabinga","year":"2000","journal-title":"Br J Cancer"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0b013e3282ff6275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:28:55Z","timestamp":1620970135000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-200805110-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,11]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e3282ff6275","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5,11]]}}}